Top Healthtech And Biotech Startups In Denmark To Watch In 2027

This piece is a list of Danish healthtech and biotech startups to watch in 2027. The companies work on drug discovery, drug delivery and treatments for cancer, diabetes complications and rare muscle disease, and some of the platforms use AI and automation. Some have just closed record funding rounds, while others have been in the lab since 2015.

The article places the startups against an established life-science scene anchored by Genmab and Zealand Pharma, with support from university and incubator names such as DTU and the BioInnovation Institute.

The company described in the most detail is Orbis Medicines, based in Copenhagen with a second site in Lausanne. It is building oral macrocycle drugs meant to address the targets of blockbuster injectable biologics. Its nGen platform combines automated chemistry with machine learning in what the company calls a lab-in-a-loop system. It starts from libraries of 100 billion compounds and can synthesise and analyse up to 100,000 distinct macrocycles in a matter of weeks.

Orbis closed a US$73 million Series A in 2021, led by Novo Holdings with Sofinnova Partners, DROIA Ventures and the LSP Dementia Fund participating. The money funds small-molecule programmes aimed at neuronal dysfunction and neuroinflammation. These rely on a discovery engine that pairs AI-driven computational chemistry with cell-based screening.

The excerpt ends as it reaches the next entry, number 7 on the list, NMD Pharma, which is not described here. It shows how AI and automation are being built into drug discovery at Danish startups that sit alongside the country's large pharma names and its investor and incubator network.